India Coronavirus Dispatch: Vaccine cos to make profits despite low prices

A look at what Covaxin's consent form says, people who shouldn't get vaccinated, mental health could influence vaccine efficacy-news relevant to India's fight against Covid-19

SII, Bharat Biotech likely to make profits despite low prices: Industry experts

The two vaccine manufacturers that have received emergency approval for their Covid-19 inoculants—Serum Institute of India and Bharat Biotech—are expected to see profits despite the low prices at which the vaccine are being sold to the government, according to a report in ThePrint.

As the two firms did not have to incur significant costs in research and development, they will be able to achieve EBITDA (earnings before interest, taxes, depreciation, and amortisation) margins of about 40%, industry experts told ThePrint. As there are no distribution and marketing costs in the